Last chance for European nanomedicine

Nanotechnology has the power to transform healthcare. But Europe will lose out to the United States unless it can mount a coherent approach to developing nanomedicine, says a new report.

Biotech brings silver lining to pharma cloud

Last month the world's leading pharmaceutical company received simultaneous FDA approval for two new therapies. Yet neither drug was invented by the company. Both were originally developed by small biotechs.

Why big pharma needs little bio

On 26 January, in London, Science|Business organised a roundtable of executives in the biotech industry to discuss the state of the market. The consensus: investor appetite for biotech companies is on the rise.